Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans. This results in a diversified product pipeline of complex generic, follow-on biologic and novel drugs. The Company's two most advanced complex generic product candidates target marketed products, which were originally approved by the United States Food and Drug Administration as New Drug Applications. M-Enoxaparin is designed to be a generic version of Lovenox (enoxaparin sodium injection), a low-molecular weight heparin used to prevent and treat deep vein thrombosis. Its second major generic product candidate is M356, a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

Momenta (MNTA) reported earnings 30 days ago. What's next for the stock?

Momenta (MNTA) Down 16.6% Since Last Earnings Report: Can It Rebound?

It's going to take a few years to get there.

Momenta Pharmaceuticals Wants to Be the "Humira of the FcRn Space"

Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q1 2019 Results - Earnings Call Transcript

Momenta (MNTA) delivered earnings and revenue surprises of -2.22% and -57.08%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Momenta Pharmaceuticals (MNTA) Reports Q1 Loss, Misses Revenue Estimates

Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

News for Momenta Pharmaceuticals Stock (MNTA)